Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Koffiekamer Terug naar discussie overzicht

Omega Diagnostics Group [ODX] - Ready to Launch the Rocket

454 Posts
Pagina: «« 1 ... 8 9 10 11 12 ... 23 »» | Laatste | Omlaag ↓
  1. TheBiG 15 november 2020 21:56

    • TheBiG

      Lid sinds: 16 jan 2020

      Laatste bezoek: 03 mei 2024

    • Aanbevelingen

      Ontvangen: 147

      Gegeven: 15

    •    Aantal posts: 306

    Ohja en mocht er nog een MHRA approval komt voor home testing is het feest helemaal compleet.
  3. TheBiG 16 november 2020 08:24

    • TheBiG

      Lid sinds: 16 jan 2020

      Laatste bezoek: 03 mei 2024

    • Aanbevelingen

      Ontvangen: 147

      Gegeven: 15

    •    Aantal posts: 306

    Richard Sneller heeft zijn belang van 5.29% in ODX van de hand gedaan.
    Date on which the threshold was crossed or reached was 13 november.
  5. TheBiG 16 november 2020 12:43

    • TheBiG

      Lid sinds: 16 jan 2020

      Laatste bezoek: 03 mei 2024

    • Aanbevelingen

      Ontvangen: 147

      Gegeven: 15

    •    Aantal posts: 306

    Omega Diagnostics Q&A: ready to seize the significant opportunity ahead

    It’s been a few months since we featured Omega Diagnostics in our going for growth series, eager to understand how the business has progressed since, we decided to briefly speak to Chief Executive Officer Colin King and get some direct questions answered amid an ever-changing landscape.

    From broker targets to MHRA approvals and expected demand for COVID-19 testing, we put forward the key questions that our readers and ourselves were eager to know as Omega Diagnostics embarks on a potentially transformational year.

    So without further ado, let’s get started:

    1. How do you think news of the COVID-19 vaccine breakthrough alters the landscape for Omega Diagnostics over the coming months?
    Omega welcomes the recent interim analysis re. the Pfizer/BioNTech COVID-19 vaccine candidate and news that we may be closer to an effective vaccine. Antibody testing, and the AbC-19 Rapid Test in particular, can play what the Company believes to be an instrumental role in assessing initial immune responses, and in determining where follow-up or booster campaigns may be needed.

    The role of antibody testing is also likely to provide a long term use of the tests and given the number of vaccines worldwide presents a considerable opportunity.

    2. Regarding the ABC-19 antibody tests, could you clarify that the MHRA approval is still in progress?
    Yes, the process is ongoing and despite it taking longer than expected we still remain confident that we will receive approval.

    Omega cannot comment further at this stage until a decision has been made, however, rest assured, when there is an update to me made Omega will announce news via RNS.

    3. What opportunities are there to sell the ABC-19 antibody tests beyond the UK and will this generate better margins for Omega Diagnostics than with the UK RTC?
    The Company is confident there is a significant opportunity to sell the ABC-19 antibody tests beyond the UK, due to product performance, and its link to the UK Government.

    The consortium is actively looking at other markets across the world including the US and yes this will generate better margins.

    All profits generated above the Government pricing will be shared equally amongst members.

    4. You recently forecast production to scale to 2m lateral flow tests per week by April with the majority coming from ‘other’ rather than UK-RTC. Is this still on track and what does ‘other’ represent?
    We remain on track to increase our capacity as outlined in the recent shareholder presentation. The other demand is forecast to be largely made up of Antigen tests however, CD4 and our own brand Antibody tests will also contribute to this overall demand. If you recall the rationale for building the capacity is that it could be adjusted based on demand.

    For example, if early in the new year there is a greater requirement for antigen testing we will focus our efforts there but if antibody testing as a result of a vaccine requires greater capacity later in the year we can move capacity.

    5. Brokers have struggled to put a target price on Omega Diagnostics in recent months. What do you think the barriers are to this and do you think it will become viable to do so soon?
    finnCap’s price target is under review given the difficulty in forecasting revenues from COVID-19 antibody and antigen tests with any degree of accuracy. When that changes then we would expect finnCap to consider a target price.

    That said, they have made it clear that even without firm forecasts or a target price the valuation upside is considered substantial and they have provided a very helpful assessment of potential revenues and gross profits at different utilisation rates in their note from 22 June 2020.

    6. Let’s assume 1 year from now COVID-19 has come and gone. What’s the vision for where Omega Diagnostics will be?
    Omega has a diversified portfolio of diagnostic tests including Food Intolerance and CD4 testing for HIV, as well as Covid, and is well funded and positioned to benefit from the opportunities and exist for growth globally though our established distribution partners.

    As mentioned above we would expect on-going demand for the UK-RTC due to the vaccine to go beyond the one year window.

    In addition with the CHAI initiative for CD4 on-going we would expect more countries to have adopted the advanced disease initiative and therefore drive increased sales.

    www.sharebuyers.co.uk/shares/omega-di...
  7. börse.de 16 november 2020 22:05

    • börse.de

      Lid sinds: 19 mrt 2020

      Laatste bezoek: 02 mei 2024

    • Aanbevelingen

      Ontvangen: 355

      Gegeven: 479

    •    Aantal posts: 1.009

    Flinke Sof vandaag, na aanvankelijk een spectaculaire ochtend; moderna nieuws gooide roet in het eten ( ook bij NVCT); herstel komt; vaccineren en testen gaan hand in hand,
  11. TheBiG 17 november 2020 14:10

    • TheBiG

      Lid sinds: 16 jan 2020

      Laatste bezoek: 03 mei 2024

    • Aanbevelingen

      Ontvangen: 147

      Gegeven: 15

    •    Aantal posts: 306

    Yorkshire developed Covid-19 test approved for use in North America

    A Covid-19 rapid antibody test, developed by York-based medical device manufacturer Abingdon Health, is to be used to detect this illness in the USA.

    Abingdon has been notified by the US Food and Drug Administration (FDA) that it will now be able to distribute its UK-RTC AbC19™ Rapid Test in the USA to laboratories and to healthcare workers, for point of care testing.

    Distribution of the test will be through CIGA Healthcare, a member of the UK-Rapid Test Consortium. (UK-RTC)

    www.thebusinessdesk.com/yorkshire/new...
  12. TheBiG 17 november 2020 14:14

    • TheBiG

      Lid sinds: 16 jan 2020

      Laatste bezoek: 03 mei 2024

    • Aanbevelingen

      Ontvangen: 147

      Gegeven: 15

    •    Aantal posts: 306

    OMEGA DIAGNOSTICS GROUP PLC

    ("Omega" or the "Company" or the "Group")



    UK-RTC Update



    Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner.



    The UK-RTC press release announces that Abingdon Health ("Abingdon") has received confirmation from the US Food and Drug Administration ("FDA") that Abingdon has completed the notification process under the FDA's Policy for Coronavirus Disease Tests During the Public Health Emergency ("the Policy").



    The Policy states that the FDA does not intend to object to a manufacturer distributing serology tests to laboratories that are certified under CLIA1 certification to perform high complexity testing where the test has been validated and while the manufacturer is preparing its Emergency Use Authorization ("EUA") request.



    Abingdon has submitted an EUA to the FDA for the AbC-19™ Rapid Test as a point of care test and the Company looks forward to learning how the EUA procedure progresses.



    A full copy of the UK-RTC press release is at the bottom of this announcement.



    1 CLIA or the Clinical Laboratory Improvement Amendments (42 CFR Part 493) are those regulations that were established in 1988 for the regulation and quality assurance of human specimens within clinical laboratory environments.
  16. Wiz@rD 18 november 2020 10:47

    • Wiz@rD

      Lid sinds: 16 okt 2020

      Laatste bezoek: 08 feb 2024

    • Aanbevelingen

      Ontvangen: 15

      Gegeven: 15

    •    Aantal posts: 168

    Odx is weer stilletjes naar beneden aan het gaan. Ik denk niet ooit mijn gak van 95 te halen

  17. [verwijderd] 18 november 2020 10:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Wiz@rD schreef op 18 november 2020 10:47:

    Odx is weer stilletjes naar beneden aan het gaan. Ik denk niet ooit mijn gak van 95 te halen

    Waarom zou het nooit meer omhoog gaan?
  18. [verwijderd] 18 november 2020 12:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Wiz@rD schreef op 18 november 2020 10:47:

    Odx is weer stilletjes naar beneden aan het gaan. Ik denk niet ooit mijn gak van 95 te halen

    Ik heb voor de beeldvorming het koersverloop van ODX even naast die van Novacyt gelegd en de twee verschillen niet veel van elkaar. Sterker nog, het koersverloop is grotendeels gelijk.

    imgur.com/a/bo91o8g
  19. Wiz@rD 18 november 2020 14:04

    • Wiz@rD

      Lid sinds: 16 okt 2020

      Laatste bezoek: 08 feb 2024

    • Aanbevelingen

      Ontvangen: 15

      Gegeven: 15

    •    Aantal posts: 168

    Maar novacyt heeft al veel cash opgebouwd, odx zie ik hier minder van. Ook minder straf forum :-)
  20. Fluxx 18 november 2020 22:45

    • Fluxx

      Lid sinds: 12 mrt 2020

      Laatste bezoek: 19 jul 2022

    • Aanbevelingen

      Ontvangen: 153

      Gegeven: 20

    •    Aantal posts: 386

    ODX is zeker geen Novacyt. Echter is de waardering er ook niet naar. Huidige market cap is 93 miljoen. Een deal zoals nu rond gaat van 75 miljoen. Is direct bijna de hele beurswaarde.

    Gaat dit aandeel nog naar de 0.95? Ja ik weet het zeker. De anti testen moeten de komende maanden gemaakt en verkocht worden. Twijfel je over je gak, en heb je de mogelijkheid. Verlaag m dan nu met de huidige aanbieding prijzen.
454 Posts
Pagina: «« 1 ... 8 9 10 11 12 ... 23 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.286
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.455
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.944
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.479
Aedifica 2 832
Aegon 3.257 320.092
AFC Ajax 537 7.018
Affimed NV 2 5.762
ageas 5.843 109.779
Agfa-Gevaert 13 1.862
Ahold 3.536 73.983
Air France - KLM 1.024 34.348
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.774
Alfen 12 16.539
Allfunds Group 3 1.217
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 337
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.767
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.368
AMG 965 125.860
AMS 3 73
Amsterdam Commodities 303 6.522
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.162
Apollo Alternative Assets 1 17
Apple 5 316
Arcadis 251 8.623
Arcelor Mittal 2.024 318.667
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.113
Aroundtown SA 1 176
Arrowhead Research 5 9.283
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.702
ASML 1.762 77.058
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.669
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 06 mei

    1. China inkoopmanagersindex diensten april
    2. PostNL Q1-cijfers
    3. Siemens Healthineers Q1-cijfers
    4. TKH Q1-cijfers
    5. Dui inkoopmanagersindex diensten april (def)
    6. EU inkoopmanagersindex diensten april (def) 52,9
    7. VK inkoopmanagersindex diensten april (def)
    8. EU producentenprijzen maart
    9. Tyson Foods Q1-cijfers

  2. 07 mei

    1. Japan inkoopmanagersindex diensten april
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda